Dystrophin Immunity in Duchenne's Muscular Dystrophy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the first mini-dystrophin clinical trial (NCT00428935), completed in 2010, most parsimoniously failed due to immune responses developed against the transgene, which was delivered in the biceps muscle using the AAV2.5 vector [122].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [122]
In the citing paper
“To date, transgene immune responses in AAV gene therapy have been mostly reported in muscle-directed clinical trials [94, 115–119].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Similarly, capsid-specific T-cell responses were limited or not observed in DMD clinical trials [94, 95].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Interestingly, pre-existing cellular immunity to dystrophin may occur in some patients with Duchene’s muscular dystrophy, a disease characterized by muscle regeneration and some level inflammation (55).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
In the citing paper
“In clinical trials, CD8+ T cell responses have been observed against dystrophin and α1-antitrypsin in treatment of Duchenne’s muscular dystrophy and α1-antitrypsin (AAT) deficiency, respectively (55, 56).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citation
Research works printed but not linked: 1
- Klein CJ, 1992, Am J Hum Genet, 50, 950
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationIn vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“99 In another study of intramuscular gene transfer for a 1 -antitrypsin de fi ciency, 98 vector administration was associated with detection of capsid-speci fi c T-cell reactivity and increase in serum creatine kinase in some subjects at approximately day 30 post vector administration.”
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Self-citationImmune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“Some patients with Duchenne muscular dystrophy may actually have pre-existing T cell immunity because of occasional endogenous dystrophin expression in revertant fibers.(81) Because overexpression of utrophin can partially compensate for lack of dystrophin, AAV vectors expressing this “self-gene” that is widely expres…”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“The first evidence of transgene-specific cytolytic T cell activation came from a phase I/II trial of intramuscular gene transfer of a microdystrophin transgene.(73) In this trial, lack of transgene expression was associated with the development of a CD8 T cell responses directed against epitopes mapping within the tra…”
BackgroundA Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617
Li, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.10.013 · Cited by 471
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Self-citationAllen, D. G., Whitehead, N. P., & Froehner, S. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00007.2015 · Cited by 426
“Only minimal and transient expression of the mini-dystrophin was detected (278).”
BackgroundMendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Self-citationPhase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Self-citationDystrophin-Deficient Cardiomyopathy
Kamdar, F., & Garry, D. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.081 · Cited by 384
“In a human pre-clinical trial of mini-dystrophin gene transfer, 6 patients with DMD received injections of mini-dystrophin, but none demonstrated significant increases in dystrophin levels and 1 patient had an immune response (112,113).”
Therapeutic developments for Duchenne muscular dystrophy
Verhaart, I. E. C., & Aartsma-Rus, A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0203-3 · Cited by 377
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“In particular, evidence of T cell-mediated anti-transgene cytotoxic T cell responses was documented in a phase I/II trial of intramuscular gene transfer in Duchenne muscular dystrophy patients (85).”
BackgroundDuchenne and Becker Muscular Dystrophies
Flanigan, K. M. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.05.002 · Cited by 317
Duchenne Muscular Dystrophy: From Diagnosis to Therapy
Falzarano, M., Scotton, C., Passarelli, C., & Ferlini, A. (2015) · Molecules · doi:10.3390/molecules201018168 · Cited by 292
“Previous studies reported that the intramuscular injections of mini-dystrophin delivered by AAV result in low levels of local dystrophin restoration and in an immunogenicity of the transgene product [55,56].”
ResultTedesco, F. S., Gerli, M. F. M., Perani, L., Benedetti, S., Ungaro, F., Cassano, M., Antonini, S., Tagliafico, E., Artusi, V., Longa, E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003541 · Cited by 301
The Pathogenesis and Therapy of Muscular Dystrophies
Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 302
“The advantage of a compensatory approach is that it is applicable to all patients independent of the type of mutation while avoiding an immune response such as that observed following minidystrophin gene replacement (159).”
BackgroundHastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
“5 capsid was detected and the safety of the vector was established.(65,83) Long-term monitoring is ongoing with new phase II studies looking at limb infusion with long-term objective of rescuing upper limb mobility followed by systemic whole-body gene transfer in DMD patients.”
Self-citationKaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
“While initial studies exploited the prototype AAV serotype 2 vector, the portfolio of AAV vectors has recently been expanded to include additional serotypes and even engineered capsids (Mendell et al, 2010; Mingozzi & High, 2013).”
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
Hathout, Y., Brody, E., Clemens, P. R., Cripe, L., DeLisle, R. K., Furlong, P., Gordish-Dressman, H., Hache, L., Henricson, E., Hoffman, E. P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507719112 · Cited by 290
“Promising therapeutic approaches for DMD include restoring expression of the dystrophin gene via exon-skipping strategies (11–13), viral-based gene therapies (14, 15), and nonsense suppression/read-through strategies (16).”
BackgroundGene therapy advances: A meta-analysis of AAV usage in clinical settings
Au, H. K. E., Isalan, M., & Mielcarek, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.809118 · Cited by 284
“Key examples include minidystrophin for muscular dystrophy and a B-domain deleted form of FVIII (BDD-FVIII) for haemophilia A (24, 63).”
BackgroundRegulatory T cells suppress muscle inflammation and injury in muscular dystrophy
Villalta, S. A., Rosenthal, W., Martinez, L., Kaur, A., Sparwasser, T., Tidball, J. G., Margeta, M., Spencer, M. J., & Bluestone, J. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009925 · Cited by 254
DNA Damage: From Threat to Treatment
Carusillo, A., & Mussolino, C. (2020) · Cells · doi:10.3390/cells9071665 · Cited by 241
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254
HLA engineering of human pluripotent stem cells
Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.59 · Cited by 253
Mendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
Self-citationTherapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches
Fairclough, R. J., Wood, M. J., & Davies, K. E. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3460 · Cited by 229
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Engineering universal cells that evade immune detection
Lanza, R., Russell, D. W., & Nagy, A. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0200-1 · Cited by 230
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
“Accordingly, transgene immunogenicity was observed in children with Duchenne muscular dystrophy following the intramuscular administration of an rAAV vector encoding the micro-dystrophin (a functional truncated version of the dystrophin protein).(117) Importantly in this study, an immune response to the vector was als…”
BackgroundProgress toward Gene Therapy for Duchenne Muscular Dystrophy
Chamberlain, J. R., & Chamberlain, J. S. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.019 · Cited by 224
“Jude Samulski, involved six patients, and while the vector injection proved safe, none of the patients expressed significant levels of micro-dystrophin (only two had any detectable exogenous dystrophin).(42) Two of the six patients displayed a low-level T cell immune response (assayed by ELISpot) against dystrophin, a…”
BackgroundResultLi, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225
Self-citationVirtual Reality for Neurorehabilitation and Cognitive Enhancement
Georgiev, D., Georgieva, I., Gong, Z., Nanjappan, V., & Georgiev, G. (2021) · Brain Sciences · doi:10.3390/brainsci11020221 · Cited by 184
“Severe paralysis may be caused by different pathogenetic mechanisms, such as spinal cord trauma [166], neurodegenerative diseases affecting the motor neurons [167], autoimmune diseases causing muscle weakness [168], or genetic muscular dystrophies [169].”
BackgroundWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
“The major challenges to date involve host immune responses and poor transduction efficiency due to limited vector tropism and poor delivery of the vector to the target cell (Manno et al. , 2006; Mingozzi et al. , 2009; Mendell et al. , 2010).”
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Challenges in DNA Delivery and Recent Advances in Multifunctional Polymeric DNA Delivery Systems
Shi, B., Zheng, M., Tao, W., Chung, R., Jin, D., Ghaffari, D., & Farokhzad, O. C. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00803 · Cited by 201
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
Bez Batti Angulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1183101 · Cited by 173
“It has been shown that viral gene delivery of dystrophin into DMD patients has been associated with an immune response, which limits the expression of dystrophin (Mendell et al., 2010).”
BackgroundCurrent Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD
Pichavant, C., Aartsma-Rus, A., Clemens, P. R., Davies, K. E., Dickson, G., Takeda, S., Wilton, S. D., Wolff, J. A., Wooddell, C. I., Xiao, X., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.59 · Cited by 193
Self-citationCanine models of Duchenne muscular dystrophy and their use in therapeutic strategies
Kornegay, J. N., Bogan, J. R., Bogan, D. J., Childers, M. K., Li, J., Nghiem, P., Detwiler, D. A., Larsen, C. A., Grange, R. W., Bhavaraju-Sanka, R. K., et al. (2012) · Mammalian Genome · doi:10.1007/s00335-011-9382-y · Cited by 186
“In a separate safety study in which an AAVminidystrophin construct was injected intramuscularly in DMD patients, T cells were shown to target the therapeutic transgene (Mendell et al. 2010).”
Self-citationGene-based therapies for neurodegenerative diseases
Sun, J., & Roy, S. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00778-1 · Cited by 187
Ousterout, D. G., Perez-Pinera, P., Thakore, P. I., Kabadi, A. M., Brown, M. T., Qin, X., Fedrigo, O., Mouly, V., Tremblay, J. P., & Gersbach, C. A. (2013) · Molecular Therapy · doi:10.1038/mt.2013.111 · Cited by 181
“It is known that in-frame deletions that occur in the exon 45-55 region contained within the rod domain can produce highly functional dystrophin proteins, and many carriers are asymptomatic or display mild symptoms.”
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update
Sun, C., Shen, L., Zhang, Z., & Xie, X. (2020) · Genes · doi:10.3390/genes11080837 · Cited by 173
“Secondary Outcome Minidystrophin gene expression and muscle strength test [88] No secondary outcome yet Microdystrophin expression and muscle motility assessment Minidystrophin gene expression, muscle strength and quality GALGT2 gene expression and muscle motility assessment Transgene expression”
BackgroundResultInfluentialDrug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
Childers, M. K., Joubert, R., Poulard, K., Moal, C., Grange, R. W., Doering, J. A., Lawlor, M. W., Rider, B. E., Jamet, T., Danièle, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007523 · Cited by 173
Chicoine, L., Montgomery, C., Bremer, W., Shontz, K., Griffin, D., Heller, K., Lewis, S., Malik, V, Grose, W., Shilling, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.244 · Cited by 167
Self-citationAntisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164
“As proteins are restored in loss-of-function diseases, activation of the immune system may complicate some of these therapies [110], though this splicing strategy still may be a promising approach for some selected diseases.”
BackgroundWallgren‐Pettersson, C., Sewry, C. A., Nowak, K. J., & Laing, N. G. (2011) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2011.10.004 · Cited by 184
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Similarly, capsid-specific T-cell responses were limited or not observed in DMD clinical trials [94, 95].”
BackgroundDurability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
“Spontaneously primed T cells were unexpectedly detected in two patients before the administration of gene therapy, with a rapid T cell response observed in one of the two patients following gene transfer, suggesting that while the mini-dystrophin protein was able to trigger memory T cells in one of the patients, the l…”
ResultTargeting RNA to treat neuromuscular disease
Muntoni, F., & Wood, M. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3459 · Cited by 157
Stem Cell–Mediated Transfer of a Human Artificial Chromosome Ameliorates Muscular Dystrophy
Tedesco, F. S., Hoshiya, H., D’Antona, G., Gerli, M., Messina, G., Antonini, S., Tonlorenzi, R., Benedetti, S., Berghella, L., Torrente, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002342 · Cited by 170
Alexander, M. S., Casar, J. C., Motohashi, N., Vieira, N. M., Eisenberg, I., Marshall, J. L., Gasperini, M. J., Lek, A., Myers, J. A., Estrella, E. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73579 · Cited by 160
“One can envision that miR-486 overexpression via adeno-associated virus (AAV) might have beneficial effects on dystrophin-defective muscles by promoting muscle hypertrophy and promoting regeneration (103).”
Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype
Vieira, N. M., Elvers, I., Alexander, M. S., Moreira, Y. B., Eran, A., Gomes, J., Marshall, J. L., Karlsson, E. K., Verjovski‐Almeida, S., Lindblad‐Toh, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.049 · Cited by 165
“Pre-clinical and clinical studies include exon-skipping (Goemans et al., 2011; Mendell et al., 2013; van Deutekom et al., 2007), AAV-delivery of µ-dystrophin (Mendell et al., 2010), and nonsense suppression to induce “readthrough” of nonsense mutations (Kayali et al., 2012).”
Arrant, A. E., Onyilo, V. C., Unger, D. E., & Roberson, E. D. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.3081-17.2018 · Cited by 159
“In two studies, nonself reactions to AAV transgenes provoked a cell-mediated immune response in which effector T cells killed muscle cells expressing the AAV transgene, resulting in gradual loss of transgene expression (Yuasa et al., 2007; Mendell et al., 2010).”
BackgroundMuscle Function Recovery in Golden Retriever Muscular Dystrophy After AAV1-U7 Exon Skipping
Vulin, A., Barthélémy, I., Goyenvalle, A., Thibaud, J. L., Beley, C., Griffith, G., Benchaouir, R., Hir, M. L., Unterfinger, Y., Lorain, S., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.181 · Cited by 161
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 163
“This has been reported against α1antitrypsin and dystrophin in AAV-based gene therapy clinical trials (Mendell et al., 2010; Calcedo et al., 2017).”
MethodKomaki, H., Nagata, T., SAITO, T. K., Masuda, S., Takeshita, E., Sasaki, M., Tachimori, H., Nakamura, H., Aoki, Y., & Takeda, S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0713 · Cited by 150
Next-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140
Current and emerging treatment strategies for Duchenne muscular dystrophy
Mah, J. K. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s93873 · Cited by 140
“However, earlier attempts in six boys with DMD due to frameshift mutations failed to achieve successful transgene expression, in part due to an unexpected primed T-cell-mediated immune response to the generated mini-dystrophin seen in two of the participants.(85) Additional clinical trials using recombinant adeno-asso…”
Guiner, C. L., Montus, M., Servais, L., Chérel, Y., François, V., Thibaud, J. L., Wary, C., Matot, B., Larcher, T., Guigand, L., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.151 · Cited by 137
Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy
Shin, J., Pan, X., Hakim, C. H., Yang, H. T., Yue, Y., Zhang, K., Terjung, R. L., & Duan, D. (2013) · Molecular Therapy · doi:10.1038/mt.2012.283 · Cited by 146
In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice
Refaey, M. E., Xu, L. M., Gao, Y., Canan, B. D., Adesanya, T. M. A., Warner, S. C., Akagi, K., Symer, D. E., Mohler, P. J., Ma, J., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310996 · Cited by 141
Paepe, B. D., & Bleecker, J. D. (2013) · Mediators of Inflammation · doi:10.1155/2013/540370 · Cited by 136
“However, surfacing results of clinical trials, more particular those using AAV-mediated delivery of minidystrophin, are suggestive of important acquisition of T cell immunity targeting the dystrophin protein [66].”
ResultTherapeutic approaches for Duchenne muscular dystrophy
Roberts, T. C., Wood, M. J. A., & Davies, K. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00775-6 · Cited by 147
“The relative failure of the first clinical trial of AAV–micro-dystrophin was attributed to such an anti-dystrophin T cell response 129 .”
BackgroundDystrophin Immunity after Gene Therapy for Duchenne’s Muscular Dystrophy
Bönnemann, C. G., Belluscio, B. A., Braun, S., Morris, C. A., Singh, T., & Muntoni, F. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2212912 · Cited by 130
Large-scale recombinant adeno-associated virus production
Kotin, R. M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr141 · Cited by 137
Yue, Y., Pan, X., Hakim, C. H., Kodippili, K., Zhang, K., Shin, J., Yang, H. T., McDonald, T., & Duan, D. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv310 · Cited by 131
“Considering the potential immunogenicity of dystrophin (24,28), we extended immune suppression to the end of the study (Fig.”
BackgroundEngineered skeletal muscles for disease modeling and drug discovery
Wang, J., Khodabukus, A., Rao, L., VanDusen, K. W., Abutaleb, N. O., & Bursac, N. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119416 · Cited by 133
Gene therapy for muscular dystrophy: Lessons learned and path forward
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Malik, V., Kaspar, B. K., Walker, C. M., & Clark, K. R. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.04.078 · Cited by 145
“These pre-clinical studies set the stage for the first human trial of gene therapy in DMD [27].”
BackgroundMethodSelf-citationEmerging therapies for Duchenne muscular dystrophy
Markati, T., Oskoui, M., Farrar, M. A., Duong, T., Goemans, N., & Servais, L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00125-9 · Cited by 127
Adeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
“This was the case in an AAV DMD clinical trial, in which patient 5 developed CD8+ T cells against a deleted region of the endogenous mutant dystrophin that was present on the therapeutic protein [30].”
BackgroundMethodInfluentialSelf-citationDevelopment of Novel Micro-dystrophins with Enhanced Functionality
Ramos, J. N., Hollinger, K., Bengtsson, N. E., Allen, J. M., Hauschka, S. D., & Chamberlain, J. S. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.002 · Cited by 126
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
“This has been demonstrated in nonclinical studies by the generation of antibodies against transgene proteins,(46,47) and in clinical studies with de novo CD8 T cell responses.(14,15) Even pre-existing immunity against the transgene protein is possible, especially in patients pretreated with replacement therapies.”
ResultThe Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology
van Putten, M., Hulsker, M., Nadarajah, V. D., van Heiningen, S. H., van Huizen, E., van Iterson, M., Admiraal, P. J. J., Messemaker, T. C., den Dunnen, J. T., Hoen, P. A. C. ’., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031937 · Cited by 120
“BMD like) dystrophin [5–12].”
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
“Also, the host immune system in patients with inborn genetic mutations may recognize the wild-type transgene product as foreign, as in AAVmediated gene therapy for Duchenne muscular dystrophy [61].”
BackgroundAAV-based gene therapies for the muscular dystrophies
Crudele, J. M., & Chamberlain, J. S. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz128 · Cited by 125
“While clinical trials with microdystrophins are showing promising results, the limited transgene size and threat of an anti-dystrophin immune response (23) have led some groups and companies to pursue alternative strategies.”
BackgroundVoors, A. A., Davison, B. A., Felker, G. M., Ponikowski, P. P., Unemori, E., Cotter, G., Teerlink, J. R., Greenberg, B., Filippatos, G. S., Teichman, S. L., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr060 · Cited by 116
Flanigan, K. M., Campbell, K., Viollet, L., Wang, W., Gomez, A. M., Walker, C. M., & Mendell, J. R. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.092 · Cited by 115
“In that clinical gene therapy trial we identified a subject in whom T cell responses developed that were directed toward epitopes encoded by exons present in the transgene but absent in the patient’s genomic DNA (patient 5 in Mendell et al. , 2010).”
InfluentialSelf-citationHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“Published online 10 September 2013 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/rmv.1762 R E V I E W Adeno-associated v therapy: immune ch Reviews in Medical Virology *Correspondence to: G Centre for Stem Cell 632004, Tamil Nadu, E-mail: jay@cmcvellor Abbreviations used AAV, adeno-associate dendritic…”
ResultInfluentialGoyenvalle, A., Babbs, A., Wright, J., Wilkins, V., Powell, D., García, L., & Davies, K. E. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds082 · Cited by 114
“(50), intramuscular injections of rAAV2-minidystrophin resulted in robust mini-dystrophin-specific T-cell activity and none of the six patients injected displayed any detectable exogenous dystrophin.”
BackgroundHakim, C. H., Wasala, N. B., Pan, X., Kodippili, K., Yue, Y., Zhang, K., Yao, G., Haffner, B., Duan, S. X., Ramos, J. N., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.06.006 · Cited by 118
“On the other side, a phase I trial has been conducted to deliver a highly shrunk micro-dystrophin gene by direct muscle injection.(40) To develop single AAV gene therapy for DMD, researchers have invented synthetic microgenes that carry only one-third of the dystrophin coding sequence.”
BackgroundTherapeutic approaches to muscular dystrophy
Goyenvalle, A., Seto, J. T., Davies, K. E., & Chamberlain, J. S. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr105 · Cited by 127
“(54), intramuscular injections of rAAV2-minidystrophin into the biceps of six patients showed robust mini-dystrophin-specific T-cell activity from as early as day 15 post-vector treatment in one patient.”
BackgroundGenetics and Emerging Treatments for Duchenne and Becker Muscular Dystrophy
Wein, N., Alfano, L. N., & Flanigan, K. M. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.03.008 · Cited by 104
Cell–matrix interactions in muscle disease
Carmignac, V., & Durbeej, M. (2011) · The Journal of Pathology · doi:10.1002/path.3020 · Cited by 113
Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients
Duan, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.012 · Cited by 110
“An early local injection trial suggests that the T-cell immune response to dystrophin may constitute a barrier in patients.(13) In this case, patients will have to be carefully selected based on the configuration of the microgene to minimize cellular immune reaction.”
BackgroundNon-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models
Song, Y., Morales, L., Malik, A. S., Mead, A. F., Greer, C. D., Mitchell, M. A., Petrov, M. T., Su, L. T., Choi, M. E., Rosenblum, S. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0594-0 · Cited by 108
Emerging drugs for Duchenne muscular dystrophy
Malik, V., Rodino‐Klapac, L. R., & Mendell, J. R. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.691965 · Cited by 113
“Upregulation of utrophin holds particular advantage because of the unlikely occurrence of an immune response as seen following mini-dystrophin gene replacement [36].”
BackgroundInfluentialSelf-citationRegulatory T cells in skeletal muscle repair and regeneration: recent insights
Wu, J., Ren, B., Wang, D., & Lin, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05142-8 · Cited by 108
“Recently, dystrophin-specific T cell responses were observed in a subset of patients with myotonic dystrophy treated with Treg-related gene therapy alleviating inflammation and suppressing the immune response [117, 118].”
BackgroundCell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner‐Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 112
“Vector-encoded transgene product may be recognized as a foreign antigen, especially if the recipient of gene transfer is not tolerant to the protein encoded by the vector, thus triggering immune responses that can result in production of transgene-specific neutralizing antibodies (40) or triggering of T cell responses…”
BackgroundKim, J. H., Kwak, H., Thompson, L. V., & Lawler, J. M. (2012) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-012-9330-9 · Cited by 112
“Gene therapy or cell therapy to restore the dystrophin missing from the DGC are promising, but one clinical trial has not yet produced convincing benefit in DMD patients (Mendell et al. 2010).”
Background
Metadata
- Authors
- Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., Malik, V., Coley, B., Clark, K. R., Li, J., Xiao, X., Samulski, J., McPhee, S. W., Samulski, R. J., & Walker, C. M.
- Affiliations
- Nationwide Children's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- AskBio (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1429-1437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3014106
- OpenAlex
- W2116885047
- Cited by
- 655
- References
- 25
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 38 · 2023: 44 · 2022: 49 · 2021: 42 · 2020: 44 · 2019: 47 · 2018: 31 · 2017: 42 · 2016: 28 · 2015: 47 · 2014: 34 · 2013: 54 · 2012: 60
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI060388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, dystrophin, autoreactive T cells, T cell immunity, dystrophin gene deletion
- MeSH terms
- Dependovirus, Autoantibodies, Child, DNA, Viral, Genetic Vectors, Humans, Immunity, Cellular, Male, T-Lymphocytes, Protein Biosynthesis, Genetic Therapy, Autoimmunity, Dystrophin, Frameshift Mutation, Muscle, Skeletal, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.